Literature DB >> 1916169

Outcome of injection sclerotherapy using absolute alcohol in patients with cirrhosis, non-cirrhotic portal fibrosis, and extrahepatic portal venous obstruction.

R Kochhar1, M K Goenka, S K Mehta.   

Abstract

In order to assess the comparative efficacy and safety of endoscopic injection sclerotherapy in patients with portal hypertension of different etiology, i.e., cirrhosis, non-cirrhotic portal fibrosis, and extrahepatic portal venous obstruction, 87 patients with variceal bleeding were initiated on sclerotherapy using absolute alcohol. There was no significant difference in the success rate of sclerotherapy as well as in the number of sessions and volume of alcohol required for variceal obliteration between the three groups. Major complications included esophageal ulcers (30.0%), symptomatic strictures (18.6%), and interval re-bleed (17.1%) with similar complication rates for the three groups (p greater than 0.05). There was no difference between patients with Child's class A cirrhosis compared with classes B and C together with respect to efficacy and complications of sclerotherapy. Fifty patients (25 cirrhosis, 11 non-cirrhotic portal fibrosis, and 14 extrahepatic portal venous obstruction) with complete variceal obliteration were followed up for a mean period of 16.5 months. Sixteen patients (32%) had variceal recurrence, but bleeding due to recurrent varices occurred in only one case. There was no difference among the three groups for overall variceal recurrence, although recurrence tended to be somewhat later in extrahepatic portal venous obstruction (9.4 +/- 4.0 months) compared with that in cirrhosis (5.1 +/- 3.6 months) and non-cirrhotic portal fibrosis (4.8 +/- 2.6 months).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1916169     DOI: 10.1016/s0016-5107(91)70780-3

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  5 in total

Review 1.  Historical overview and review of current day treatment in the management of acute variceal haemorrhage.

Authors:  Neil Rajoriya; Dhiraj Tripathi
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

Review 2.  Noncirrhotic portal hypertension.

Authors:  Harshal Rajekar; Rakesh K Vasishta; Yogesh K Chawla; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2011-11-09

3.  Noncirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and treatment.

Authors:  Shiv Kumar Sarin; Ashish Kumar; Yogesh Kumar Chawla; Sanjay Saran Baijal; Radha Krishna Dhiman; Wasim Jafri; Laurentius A Lesmana; Debendranath Guha Mazumder; Masao Omata; Huma Qureshi; Rizvi Moattar Raza; Peush Sahni; Puja Sakhuja; Mohammad Salih; Amal Santra; Barjesh Chander Sharma; Praveen Sharma; Gamal Shiha; Jose Sollano
Journal:  Hepatol Int       Date:  2007-09-11       Impact factor: 6.047

4.  Sclerotherapy in noncirrhotic portal fibrosis.

Authors:  Y K Chawla; J B Dilawari; R K Dhiman; M K Goenka; D K Bhasin; R Kochhar; K Singh; U Kaur
Journal:  Dig Dis Sci       Date:  1997-07       Impact factor: 3.199

5.  Effects of alcohol injection in rat sciatic nerve as a model for Morton's neuroma treatment.

Authors:  Mathew J Mazoch; Gulraiz A Cheema; Larry J Suva; Ruth L Thomas
Journal:  Foot Ankle Int       Date:  2014-08-05       Impact factor: 2.827

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.